Bristol-Myers Squibb, BAC to develop CaptureSelect ligands for purification of Adnectins

BAC BV, the leading provider of antibody based affinity purification technology, has announced a collaboration with Bristol-Myers Squibb Company (NYSE:BMY) to generate CaptureSelect^® affinity ligands for applications in the purification and analysis of a proprietary type of targeted biologic, called Adnectins™. Derived from human fibronectin, Adnectins are engineered using Bristol-Myers Squibb's proprietary PROfusion™ technology to either block or stimulate the action of specific targets across a broad range of therapeutic areas.

The collaboration will focus on discovering and developing custom CaptureSelect^® ligands for the routine purification of Adnectin biologics.

"Our CaptureSelect platform enables us to produce ligands that have high affinity and specificity for individual proteins and facilitates the generation of an exceptionally pure product in a single purification step," commented Laurens Sierkstra, CEO of BAC. "We are delighted to collaborate with Bristol-Myers Squibb on the development of ligands for their Adnectin proteins. These custom ligands should simplify the purification process."